New Method for Identifying Apoptosis Drug Candidates

Information

  • Research Project
  • 7667592
  • ApplicationId
    7667592
  • Core Project Number
    R43GM087754
  • Full Project Number
    1R43GM087754-01
  • Serial Number
    87754
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    7/1/2009 - 15 years ago
  • Project End Date
    2/28/2011 - 14 years ago
  • Program Officer Name
    PORTNOY, MATTHEW
  • Budget Start Date
    7/1/2009 - 15 years ago
  • Budget End Date
    2/28/2011 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/22/2009 - 15 years ago

New Method for Identifying Apoptosis Drug Candidates

DESCRIPTION (provided by applicant): The overall aim of this research is to develop a rapid, quantitative microplate-based whole animal zebrafish caspase assay which can be used to identify apoptosis inducers and inhibitors. We will validate the assay with known inhibitors and inducers of apoptosis and compare our findings with results observed in cell and mammalian assays. Since the early-mid 1990's, numerous, diverse assays for measuring apoptosis have been developed paralleling the increased interest in apoptosis research. Apoptosis is an evolutionarily conserved mechanism, and homologs of the endoproteases responsible for cell death, caspases, have been identified in several metazoans, including zebrafish. Because of their genetic and physiological similarity to humans, zebrafish show promise as an efficient animal model for drug screening. Zebrafish is exceptionally well suited for studies that combine cellular, molecular, and genetic approaches. Because zebrafish develop rapidly, drug effects can be observed within days instead of weeks or months. Zebrafish embryos are completely transparent, facilitating observation and analysis. PUBLIC HEALTH RELEVANCE: In the current proposal, we will develop a quantitative caspase assay in whole zebrafish. By providing a rapid assay for prescreening drug candidates prior to performing expensive mammalian testing, the proposed zebrafish assay will facilitate drug development for certain forms of cancer, was well as other diseases including: autoimmune diseases, tissue damage, inflammatory disease, AIDS, and neurodegenerative diseases.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    199439
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:199439\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYLONIX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    071479849
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES